Page last updated: 2024-11-11

zatosetron

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

zatosetron: structure given in first source; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6918154
CHEMBL ID2111147
SCHEMBL ID466401
SCHEMBL ID466399
MeSH IDM0178595

Synonyms (18)

Synonym
ly277359
ly-277359
5-chloro-2,3-dihydro-2,2-dimethyl-n-1alphah,5alphah-tropan-3alpha-yl-7-benzofurancarboxamide
zatosetron [inn:ban]
7-benzofurancarboxamide, 5-chloro-2,3-dihydro-2,2-dimethyl-n-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-, endo-
zatosetron
zatosetronum [inn-latin]
5-chloro-2,2-dimethyl-n-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-3h-1-benzofuran-7-carboxamide
zatosetronum
901mc95xsb ,
unii-901mc95xsb
5-chloro-2,3-dihydro-2,2-dimethyl-n-1.alpha.h,5.alpha.h-tropan-3.alpha.-yl-7-benzofurancarboxamide
zatosetron [who-dd]
zatosetron [inn]
CHEMBL2111147
SCHEMBL466401
SCHEMBL466399
5-chloro-2,2-dimethyl-n-[(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-3h-1-benzofuran-7-carboxamide

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Zatosetron treatment inhibited and delayed ipecac-induced emesis in both groups."( Effect of zatosetron on ipecac-induced emesis in dogs and healthy men.
Cerimele, BJ; Gidda, JS; Goldberg, MJ; Schwartz, SM, 1994
)
1.41

Dosage Studied

ExcerptRelevanceReference
" However, there was a mild increase in the Q-Tc interval throughout the treatment period at 4 hours postdosing in monkeys in the middle- and high-dose groups and a slight increase prior to dosing in animals in the high-dose group."( Chronic toxicity of zatosetron, a 5-HT3 receptor antagonist, in rhesus monkeys.
Adams, E; Bendele, A; Hanasono, G; Means, J; Schmalz, C; Shoufler, J; Symanowski, J, 1995
)
0.61
" Plasma concentrations of zatosetron and its 3-hydroxy metabolite increased with increasing dose and duration of dosing in both males and females during the first 6 months of dosing."( Chronic toxicity, metabolism, and pharmacokinetics of the 5-HT3 receptor antagonist zatosetron (LY277359) in Fischer 344 rats.
Bendele, AM; Buenger, DA; Hanasono, GK; McGrath, JP; Schmalz, CA, 1994
)
0.81
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID6104Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID6255Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives.
AID281799Displacement of [3H]strychnine from glycine receptor in Wistar rat spinal cord synaptosomal membranes2004Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25
Synthesis of tropeines and allosteric modulation of ionotropic glycine receptors.
AID6107Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID6256Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives.
AID6054Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID60965-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID54913Inhibition of cytochrome P450 3A42002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
A neural network based virtual screening of cytochrome P450 3A4 inhibitors.
AID6110Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID5992The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives.
AID6115Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID6111Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID5968In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID6116Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID60925-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats)1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID6055Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID6108Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID6109Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID6117Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID6105Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
AID243422log (1/Km) value for human liver microsome cytochrome P450 3A42005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's19 (82.61)18.2507
2000's4 (17.39)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.95 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (11.54%)5.53%
Reviews1 (3.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (84.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]